The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] Ness-Abramof, 2002, Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese., Obes Res sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] Smith, 1996, Localization of 11β-hydroxysteroid dehydrogenase type II in human epithelial tissues., J Clin Endocrinol Metab source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] Pecori Giraldi, 2007, Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series., J Clin Endocrinol Metab source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] Batista, 2007, Diagnostic tests for children who are referred for the investigation of Cushing syndrome, Pediatrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 801–900 of 2,716
Factors Affecting Dexamethasone Suppression Test Results
Berlińska, A., Świątkowska-Stodulska, R., & Sworczak, K. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1017-3217 · Cited by 22
The Demystification of Secondary Hypertension: Diagnostic Strategies and Treatment Algorithms
Hirsch, J. S., & Hong, S. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0790-8 · Cited by 26
Cushing's syndrome – Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies
Ragnarsson, Ó. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101382 · Cited by 25
Akbari, H., Ghorbani, M., Kabootari, M., Mehrjardi, A. Z., Tehrani, M. R. M., Malek, M., & Khamseh, M. E. (2020) · British Journal of Neurosurgery · doi:10.1080/02688697.2020.1736263 · Cited by 22
“Fifteen patients were confirmed to have CD.”
BackgroundMethodInfluentialCirculating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease
Guarnotta, V., Prinzi, A., Pitrone, M., Pizzolanti, G., & Giordano, C. S. D. S. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s249090 · Cited by 24
The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline.
Gilbert, R., & Lim, E. M. (2008) · PubMed · Cited by 23
Starker, L. F., Kunstman, J. W., & Carling, T. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.02.008 · Cited by 25
Late-night salivary cortisol in normal subjects and in patients with Cushing’s syndrome
Jeyaraman, K., Ammini, A. C., Nandita, G., & Dwivedi, S. N. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2009.090787 · Cited by 21
Valassi, E., Aulinas, A., Glad, C. A. M., Johannsson, G., Ragnarsson, Ó., & Webb, S. M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13414 · Cited by 23
Fleseriu, M., Ludlam, W. H., Teh, S. H., Yedinak, C. G., Deveney, C. W., & Sheppard, B. C. (2008) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2008.09.011 · Cited by 22
Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women
Elhassan, Y., Hawley, J. M., Cussen, L., Abbara, A., Clarke, S. A., Kempegowda, P., Dhillon‐Smith, R. K., Thadani, P., Busby, M., Owusu‐Darkwah, L., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.15265 · Cited by 31
Peripheral clock system circadian abnormalities in Cushing’s disease
Soares, V. R., Martins, C. S., Martínez, E. Z., de Araújo, L. D., Roa, S. L. R., Silva, L. R., Moreira, A. C., & de Castro, M. (2020) · Chronobiology International · doi:10.1080/07420528.2020.1758126 · Cited by 21
Neijs, L. D.-D., Leenen, P. J. M., Hays, J. P., van der Valk, E. S., Kraaij, R., van Rossum, E. F. C., & Ester, W. A. (2020) · Current Epidemiology Reports · doi:10.1007/s40471-020-00237-2 · Cited by 25
Central serous chorioretinopathy in active endogenous Cushing’s syndrome
Brinks, J., van Haalen, F. M., van Rijssen, T. J., Biermasz, N. R., Meijer, O. C., Pereira, A. M., Boon, C. J. F., & van Dijk, E. H. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-82536-2 · Cited by 21
Cushing’s syndrome is associated with sleep alterations detected by wrist actigraphy
D’Angelo, V., Beccuti, G., Berardelli, R., Karamouzis, I., Zichi, C., Giordano, R., Minetto, M. A., Maccario, M., Ghigo, E., & Arvat, E. (2015) · Pituitary · doi:10.1007/s11102-015-0667-0 · Cited by 25
“CS was diagnosed according to international criteria [13]: high 24‐h urinary free cortisol (UFC), absent cortisol suppression after low‐dose dexamethasone test (>1.”
MethodMetabolic complications of endogenous Cushing: patient selection for screening
Belaya, Z. E., Rozhinskaya, L. Y., Dragunova, N. V., Dzeranova, L. K., Marova, E. I., Arapova, S., Молитвословова, Н. Н., Zenkova, T. S., Mel'nichenko, G. A., & Dedov, I. I. (2013) · Obesity and metabolism · doi:10.14341/2071-8713-5068 · Cited by 20
The Evaluation and Treatment of Endocrine Forms of Hypertension
Velasco, A., & Vongpatanasin, W. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0528-x · Cited by 23
Is metabolic syndrome a mild form of Cushing’s syndrome?
Krikorian, A., & Khan, M. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9142-4 · Cited by 23
“Biochemical criteria for diagnosis include elevated midnight salivary cortisol, elevated 24 h urinary free cortisol, and lack of suppression with low dose dexamethasone, although no test has 100% sensitivity and specificity [11].”
BackgroundCushing’s syndrome: Why is diagnosis so difficult?
Aron, D. C. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9127-3 · Cited by 26
“Part of the difficulty in appreciating a clinically accurate gestalt is that the clinical features of Cushing’s syndrome are highly variable [7, 8, 28, 29].”
BackgroundInfluentialÅsvold, B. O., Grill, V., Thorstensen, K., & Bjørgaas, M. R. (2012) · Endocrine Connections · doi:10.1530/ec-12-0047 · Cited by 20
Dilated Cardiomyopathy Revealing Cushing Disease: A Case Report and Literature Review
Marchand, L., Segrestin, B., Lapoirie, M., Favrel, V., Dementhon, J., Jouanneau, E., & Raverot, G. (2015) · Medicine · doi:10.1097/md.0000000000002011 · Cited by 22
“INTRODUCTION E ndogenous Cushing’s syndrome may be caused by overproduction of adrenocorticotropic hormone (ACTH) (Cushing’s disease in most cases) or by an independent high cortisol secretion from the adrenal cortex.(1) Cardiovascular impairments are frequent, due to hypertension, hyperglycemia, hypercholesterolemia,…”
BackgroundAljabri, K. S., Bokhari, S., Assiri, F., Alshareef, M. A. U., & Khan, P. M. (2016) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2016.341 · Cited by 20
Stewart, P. M., & Newell-Price, J. D. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00015-0 · Cited by 35
Self-citationBeltsevich, D. G., Mel'nichenko, G. A., Kuznetsov, N. S., Troshina, E. A., Platonova, N. M., Vanushko, V. E., Yukina, M. Y., & Молашенко, Н. В. (2016) · Endocrine Surgery · doi:10.14341/serg2016431-42 · Cited by 24
“Существующие международные клинические рекомендации в отношении диагностики гиперкортицизма имеют достаточную доказательную базу [6, 7].”
Resistant Hypertension: Diagnosis and Management
Nagarajan, N., & Jalal, D. I. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.03.002 · Cited by 22
A study of thyroid functions in patients with Cushing’s syndrome: a single-center experience
Xiang, B., Tao, R., Liu, X., Zhu, X., He, M., Ma, Z., Yang, Y., Zhang, Z., Li, Y., Yao, Z., et al. (2019) · Endocrine Connections · doi:10.1530/ec-19-0309 · Cited by 22
“Approximately 80% of endogenous CS is adrenocorticotrophin (ACTH)-dependent(1), and 20% is ACTH-independent.”
BackgroundThe role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome
Ceccato, F., Cecchin, D., Gregianin, M., Ricci, G., Campi, C., Crimì, F., Bergamo, M., Versari, A., Lacognata, C. S., Rea, F., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0089 · Cited by 22
Guaraldi, F., Zoli, M., Asioli, S., Corona, G., Gori, D., Friso, F., Pasquini, E., Bacci, A., Sforza, A., & Mazzatenta, D. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01225-5 · Cited by 19
Diagnosis and Differential Diagnosis of Cushing’s Syndrome
Findling, J. W., Nieman, L. K., & Tabarin, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705984 · Cited by 21
Self-citationCote, D. J., Iuliano, S. L., Catalino, M., & Laws, E. (2020) · Neurosurgical Focus · doi:10.3171/2020.3.focus2043 · Cited by 19
Dai, C., Fan, Y., Liu, X.-H., Bao, X., Yao, Y., Wang, R., & Feng, M. (2020) · Neuroendocrinology · doi:10.1159/000509221 · Cited by 21
Telomere length and telomerase expression in pituitary tumors
Martins, C. S., Santana-Lemos, B. A. A., Saggioro, F. P., Neder, L., Machado, H. R., Moreira, A. C., Calado, R. T., & de Castro, M. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0298-3 · Cited by 23
“Diagnoses were based on internationally established criteria [6–8].”
MethodThe relation between long‐term cortisol levels and the metabolic syndrome in HIV ‐infected patients
Langerak, T., van den Dries, L. W. J., Wester, V. L., Staufenbiel, S. M., Manenschijn, L., van Rossum, E. F. C., & Gorp, E. C. M. V. (2015) · Clinical Endocrinology · doi:10.1111/cen.12790 · Cited by 23
Broder, M. S., Neary, M. P., Chang, E. Y., Cherepanov, D., & Ludlam, W. H. (2014) · Endocrine Practice · doi:10.4158/ep14126.or · Cited by 23
Recent Challenges in the Diagnosis of Cushing’s Syndrome
Giraldi, F. P. (2009) · Hormone Research in Paediatrics · doi:10.1159/000178053 · Cited by 22
Djedovic, N. K., & Rainbow, S. J. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.010250 · Cited by 21
Measurement of salivary cortisone to assess the adequacy of hydrocortisone replacement
Raff, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1228 · Cited by 19
Influence of age, gender and body mass index on late-night salivary cortisol in healthy adults
Coelli, S., Farias, C. B., Soares, A. A., Crescente, G. M., Hirakata, V. N., Souza, L. B., Czepielewski, M. A., Camargo, J. L., & Silveiro, S. P. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-1100 · Cited by 19
“It is well recognized that CBG can be affected by certain drugs and conditions, such as pregnancy and nutritional status [4, 5].”
BackgroundInfluentialBudyal, S., Jadhav, S. S., Kasaliwal, R., Patt, H., Khare, S., Shivane, V., Lila, A. R., Bandgar, T., & Shah, N. S. (2015) · Endocrine Connections · doi:10.1530/ec-15-0078 · Cited by 19
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 28
Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas
Giraldi, F. P., Cassarino, M. F., Sesta, A., Terreni, M., Lasio, G. B., & Losa, M. (2020) · Cancers · doi:10.3390/cancers12030669 · Cited by 21
“The diagnosis of Cushing’s disease had been established by standard criteria [51,95].”
BackgroundLiu, M., Lou, Y., Chen, H., Wang, Y., Zhang, Z., Li, P., & Zhu, D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac072 · Cited by 18
Evaluation of ketoconazole as a treatment for Cushing’s disease in a retrospective cohort
Viecceli, C., Mattos, A. C. V., Costa, M. C. B., de Melo, R. B., Rodrigues, T. D. C., & Czepielewski, M. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1017331 · Cited by 22
Castro, M. A., Ruiz-Sánchez, J. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Aguilera-Saborido, A., Cerezo, J. F. G., Lazareno, N. L., Quesada, M. E. T., Ramos, J. G., Oriola, J., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03751-1 · Cited by 25
“In addition, PAC levels are typically decreased if co-secretion of aldosterone is not involved [120].”
Doi, S. A. R., Clark, J. M., & Russell, A. W. (2012) · Endocrine · doi:10.1007/s12020-012-9855-0 · Cited by 19
“the case with the LNSC too [31], the most recent Endocrine Society guidelines [24] suggests that such patients (e.”
BackgroundDiagnosis of Cushing’s disease
Daniel, E., & Newell-Price, J. D. C. (2015) · Pituitary · doi:10.1007/s11102-015-0649-2 · Cited by 24
“It is recommended that investigation of whether an individual first has CS follows the Endocrine Society guidelines: specifically, there must be a strong clinical index of suspicion, and indiscriminant widespread screening of at risk populations is to be avoided [3].”
BackgroundSelf-citationClinical utility of an ultrasensitive late night salivary cortisol assay by tandem mass spectrometry
Sturmer, L. R., Dodd, D., Chao, C. S., & Shi, R. (2017) · Steroids · doi:10.1016/j.steroids.2017.11.014 · Cited by 21
“Following the Endocrine Society’s Clinical Practice Guidelines for the detection and diagnosis of patients with CS, the measurement of cortisol (urine, serum, or salivary) is the endpoint for recommended tests [4].”
InfluentialAdvances in adrenal tumors 2018
Crona, J., Beuschlein, F., Pacák, K., & Skogseid, B. M. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0138 · Cited by 20
Pathogenesis of Cushing Disease: An Update on the Genetics of Corticotropinomas
Albani, A., Perez‐Rivas, L. G., Reincke, M., & Theodoropoulou, M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0111 · Cited by 22
Elias, C. P., Antunes, D. E., Coêlho, M. S., de Lima, C. L., Rassi, N., de Melo, A. P. M., & Amato, A. A. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0396-4 · Cited by 20
Goyal, A., Kubihal, S., Gupta, Y., Jyotsna, V. P., & Khadgawat, R. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_553_19 · Cited by 21
“8 μg/dL (50 nmol/L) on a 48-h LDDST is suggestive of endogenous Cushing syndrome.[54] The 48-h LDDST is associated with improved specificity compared to the 1 mg overnight dexamethasone suppression test (ONDST).”
MethodBauerle, K. T., & Harris, C. A. (2016) · Europe PMC (PubMed Central) · Cited by 31
Titman, A., Price, V., Hawcutt, D. B., Chesters, C., Ali, M. T., Cacace, G., Lancaster, G., Peak, M., & Blair, J. (2020) · Clinical Endocrinology · doi:10.1111/cen.14294 · Cited by 20
Dalmazi, G. D., Morandi, L., Rubin, B., Pilon, C., Asioli, S., Vicennati, V., Leo, A. D., Ambrosi, F., Santini, D., Pagotto, U., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa585 · Cited by 19
Impact of cortisol on blood pressure and hypertension-mediated organ damage in hypertensive patients
Haddad, C., Courand, P., Berge, C., Harbaoui, B., & Lantelme, P. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002801 · Cited by 21
“Unau cortisol >50 nmol/l after midnight administration of 1mg dexamethasone [13].”
BackgroundFirst German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors
Deutschbein, T., Jaursch-Hancke, C., Knappe, U. J., Saeger, W., Flitsch, J., Bojunga, J., Buchfelder, M., Ditzen, B., Gerlach, R., Gertzen, E., et al. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1373-4087 · Cited by 21
Hypercortisolism in Obesity-Associated Hypertension
Varughese, A. G., Nimkevych, O., & Uwaifo, G. I. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0443-y · Cited by 23
Muth, A., Taft, C., Hammarstedt, L., Björneld, L., Hellström, M., & Wängberg, B. (2012) · Endocrine · doi:10.1007/s12020-012-9856-z · Cited by 20
Bonert, V. S., Bose, N., & Carmichael, J. D. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.12.focus14780 · Cited by 21
Cassarino, M. F., Sesta, A., Pagliardini, L., Losa, M., Lasio, G. B., Cavagnini, F., & Giraldi, F. P. (2016) · Endocrine · doi:10.1007/s12020-016-0990-x · Cited by 22
Hepşen, S., Sencar, M. E., Sakız, D., Akhanlı, P., Uçan, B., Ünsal, İ. Ö., Özbek, M., & Çakal, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108081 · Cited by 21
Association between thyroid function and serum cortisol in cortisol-producing adenoma patients
Cai, R., Zhou, W., Jiang, L., Jiang, Y., Su, T., Zhang, C., Zhou, W., Ning, G., & Wang, W. (2020) · Endocrine · doi:10.1007/s12020-020-02278-5 · Cited by 18
Multidisciplinary Team Care in Pituitary Tumours
Marques, P., Sagarribay, A., Tortosa, F., Neto, L. L., Ferreira, J. T., Subtil, J., Palha, A. M., Dias, D., & Sapinho, I. (2024) · Cancers · doi:10.3390/cancers16050950 · Cited by 25
Recognition and Management of Ectopic ACTH Secreting Tumors
Elenius, H., & Nieman, L. K. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae194 · Cited by 23
Self-citationNonfunctional adrenal incidentalomas may be related to bisphenol-A
Eker, F., Güngüneş, A., Durmaz, Ş. A., Kısa, Ü., & Celik, Z. R. (2020) · Endocrine · doi:10.1007/s12020-020-02502-2 · Cited by 19
Shichi, H., Fukuoka, H., Kanzawa, M., Yamamoto, M., Yamamoto, N., Suzuki, M., Urai, S., Matsumoto, R., Kanie, K., Fujita, Y., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01220-4 · Cited by 19
“0%), similar to that of 10 μg for diagnosing CD [3], this may also be the reason for the discrepancy.”
BackgroundDetomas, M., Ritzel, K., Nasi‐Kordhishti, I., Wolfsberger, S., Quinkler, M. O., Losa, M., Tröger, V., Kroiß, M., Faßnacht, M., Vila, G., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.955945 · Cited by 22
Impact of Cushing’s syndrome on the gonadotrope axis and testicular functions in men
Papadakis, G. E., de Kalbermatten, B., Dormoy, A., Salenave, S., Trabado, S., Vieira-Pinto, O., Richa, C., Kamenický, P., Chanson, P., Maione, L., et al. (2023) · Human Reproduction · doi:10.1093/humrep/dead187 · Cited by 20
“To focus on the effect of frank hypercortisolism, we limited the assessment to cases with elevated 24h-urinary-free cortisol (24h-UFC) on two separate occasions (normal 24-UFC range is between 1.02 and 155, the upper limit normal (ULN)) (Nieman et al. , 2008).”
BackgroundInfluentialIannetti, L., Spinucci, G., Pesci, F. R., Vicinanza, R., Stigliano, A., & Pivetti‐Pezzi, P. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2011.6449 · Cited by 18
Anderwald, C. H., Tura, A., Gessl, A., Luger, A., Pacini, G., & Krebs, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077326 · Cited by 19
“It has been generally accepted for long that a repeated, fasting, post- dexamethasone-suppression-test (DST) cortisol level above 5μg/dL (pDexa5μg/dL) is considered abnormal and brings about diagnosis of overt Cushing syndrome [19], which goes along with signs and/or symptoms specific to overt cortisol excess, such as…”
BackgroundDiagnóstico y diagnóstico diferencial del síndrome de Cushing
Santos, S., Santos, E., Gaztambide, S., & Salvador, J. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)70555-8 · Cited by 30
Secondary hypertension: a condition not to be missed
Sukor, N. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2011.118661 · Cited by 23
Indication and Technical Aspects of Adrenal Blood Sampling
Blondin, D., Quack, I., Haase, M., Kücükköylü, S., & Willenberg, H. S. (2014) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/s-0034-1385081 · Cited by 21
“Existing guidelines and recommendations provide practical assistance in this regard [33, 34].”
Shapiro, L., Elahi, S., Riddoch, F., Perry, L., Martin, L., Akker, S. A., Monson, J. P., Drake, W. M., Grossman, A. B., Savage, M. O., et al. (2016) · Hormone Research in Paediatrics · doi:10.1159/000446913 · Cited by 21
Self-citationAmbulatory Arterial Stiffness Indexes in Cushing’s Syndrome
Battocchio, M., Rebellato, A., Grillo, A., Dassie, F., Maffei, P., Bernardi, S., Fabris, B., Carretta, R., & Fallo, F. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-100385 · Cited by 18
“The initial diagnosis was based on clinical features, high urinary cortisol, loss of circadian rhythm of plasma cortisol, and failure to suppress serum cortisol to < 50 nmol/l after 1 mg dexamethasone overnight [17].”
Diagnosing endocrine hypertension: a practical approach
Yang, J., Shen, J., & Fuller, P. J. (2017) · Nephrology · doi:10.1111/nep.13078 · Cited by 22
“Cortisol-binding globulin level is raised by oestradiol excess such as in pregnancy or taking oral contraceptive pill, which therefore raises the total serum cortisol.(111,114,115) This test, however, is not recommended for patients with moderate to severe chronic renal impairment due to falsely low levels that may oc…”
BackgroundMethodInfluentialDo the diagnostic criteria for subclinical hypercortisolism exist?
Tabarin, A. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.013 · Cited by 19
Barbot, M., Guarnotta, V., Zilio, M., Ceccato, F., Ciresi, A., Daniele, A., Pizzolanti, G., Campello, E., Frigo, A. C., Giordano, C. S. D. S., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1669-2 · Cited by 19
Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series
Serban, A. L., Sindaco, G. D., Sala, E., Carosi, G., Indirli, R., Rodari, G., Giavoli, C., Locatelli, M., Carrabba, G. G., Bertani, G., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01151-1 · Cited by 18
Cyprich, J., Pangal, D. J., Rutkowski, M. J., Donoho, D. A., Shiroishi, M. S., Liu, C. J., Carmichael, J. D., & Zada, G. (2020) · Journal of neurosurgery · doi:10.3171/2019.12.jns192506 · Cited by 18
Approach to the Patient with Subclinical Cushing’s Syndrome
Ivović, M., Marina, L., Šojat, A. S., Tančić‐Gajić, M., Arizanović, Z., Kendereški, A., & Vujović, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200813134328 · Cited by 20
Rossi, C., Cicalini, I., Verrocchio, S., Dalmazi, G. D., Federici, L., & Bucci, I. (2020) · Biomedicines · doi:10.3390/biomedicines8090314 · Cited by 21
“The indications, evidence, strengths, and limitations of these tests are reviewed in the Endocrine Society Clinical Practice Guidelines [23].”
BackgroundGao, X., Yamazaki, Y., Tezuka, Y., Pieroni, J., Ishii, K., Atsumi, N., Ono, Y., Omata, K., Morimoto, R., Nakamura, Y., et al. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105764 · Cited by 19
Sagan, K. P., Andrysiak-Mamos, E., Tyburski, E. M., Sagan, L. M., & Syrenicz, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091879 · Cited by 18
“Firstly, according to the Polish Society of Endocrinology, patients from the study group received somatostatin analogues (SSA) preoperatively [15], which improves QoL in patients with acromegaly [34].”
MethodKatabami, T., Ishii, S., Obi, R., Asai, S., & Tanaka, Y. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0281 · Cited by 18
“The American Endocrine Society published clinical practice guidelines for Cushing’s syndrome (CS) in 2008 [11] and advocated that the cortisol level threshold after overnight 1-mg DST should be lowered to < 1.”
BackgroundPRKACA Mutations in Adrenal Adenomas: Genotype/Phenotype Correlations
Dalmazi, G. D., & Beuschlein, F. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-120416 · Cited by 19
“%) p.L206R WES + Sanger sequencing Cao et al. 2014 [2] According to Endocrine Society guidelines Not included 57/87 (65.5 %)b n/a p.L206R WES + Sanger sequencing Sato et al. 2014 [3] According to Endocrine Society guidelines Adrenocortical incidentaloma without signs/ symptoms of CS, among patients diagnosed with cort…”
InfluentialKishino, M., Yoshimoto, T., Nakadate, M., et al. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0433 · Cited by 18
Aberle, J., Wiesch, C. S. Z., Flitsch, J., Veigel, J., Schön, G., Jung, R., Reining, F., Lautenbach, A., Rotermund, R., & Riedel, N. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0870-8 · Cited by 18
Giraldi, F. P., Pagliardini, L., Cassarino, M. F., Losa, M., Lasio, G. B., & Cavagnini, F. (2011) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02213.x · Cited by 18
Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas
Yılmaz, H., Tütüncü, N. B., & Şahin, M. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345772 · Cited by 18
Mohamed, R. S., Abuelgasim, B., Barker, S., Prabhudev, H., Martin, N. M., Meeran, K., Williams, E. L., Darch, S., Matthew, W., Tan, T., et al. (2022) · Endocrine Connections · doi:10.1530/ec-22-0050 · Cited by 18
Fleseriu, M., Auchus, R. J., Bancos, I., & Biller, B. M. K. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf027 · Cited by 23
“…normal (ULN); low ACTH [ < 2 pg/mL ( < 0.44 pmol/L)]; serum cortisol 8 μ g/dL (220.7 nmol/L) following 1 mg dexamethasone suppression test [DST; normal < 1.8 μ g/dL ( < 49.7 nmol/L); dexamethasone level 400 ng/dL (9.0 nmol/L); value for accurate result 100-> 220 ng/dL (2.25-> 5.6 nmol/L)] [66, 67].”
InfluentialSelf-citationThe Landmark Series: Evaluation and Management of Adrenal Incidentalomas
Owei, L., & Wachtel, H. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17296-8 · Cited by 21
“16 However, in patients suspected of MACS, UFC has a sensitivity of only 80–98%.”
InfluentialThe management of Cushing's disease - from investigation to treatment.
Juszczak, A., & Grossman, A. B. (2013) · PubMed · Cited by 21
Castro, M. A., Corrales, E. P., Cancela, A. A., Duque, S. G., Urzaiz, L. L., & Berrocal, V. R. (2020) · Endocrine · doi:10.1007/s12020-020-02455-6 · Cited by 16
Landry, J. P., Clemente-Gutiérrez, U., Pieterman, C. R. C., Chiang, Y., Waguespack, S. G., Jiménez, C., Habra, M. A., Halperin, D. M., Fisher, S. B., Graham, P. H., et al. (2022) · Surgery · doi:10.1016/j.surg.2022.03.014 · Cited by 21
Brosolo, G., Catena, C., Porto, A. D., Bulfone, L., Vacca, A., Verheyen, N., & Sechi, L. A. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19472 · Cited by 18
“Smokers, n (%) 31 (23) 22 (23) 9 (22) 0.”
Detomas, M., Deutschbein, T., Tamburello, M., Chifu, I. O., Kimpel, O., Sbiera, S., Kroiß, M., Faßnacht, M., & Altieri, B. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02128-x · Cited by 21
“Diagnosis of ACTH-dependent CS (including Cushing disease, CD and ectopic CS, ECS) and ACTH-independent CS (due to cortisol-producing adrenocortical adenomas, CPA and carcinomas, ACC) was made according to established diagnostic criteria [10, 11].”
MethodFarinelli, D. G., Oliveira, K. C., Hayashi, L. F., & Kater, C. E. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.09.007 · Cited by 17
A comprehensive review of the new FIGO classification of ovulatory disorders
Balen, A. H., Tamblyn, J. A., Skorupskaite, K., & Munro, M. G. (2024) · Human Reproduction Update · doi:10.1093/humupd/dmae003 · Cited by 25
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.